Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367678369> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4367678369 endingPage "472" @default.
- W4367678369 startingPage "464" @default.
- W4367678369 abstract "In this study, we retrospectively reviewed the outcomes of patients treated with one or more series of intravitreal methotrexate (MTX) injections as a surgical adjunct for the prevention of recurrent rhegmatogenous retinal detachment (RRD) related to proliferative vitreoretinopathy (PVR). The study subjects were patients with primary or recurrent RRD associated with grade C PVR, who received one or more series of 9 intravitreal MTX injections. Each series consisted of a single intraoperative MTX injection and then 8 weekly postoperative MTX injections as an off-label surgical adjunct for the prevention of PVR. The primary outcome was the retinal reattachment rate. The secondary outcome was the incidence of treatment-limiting side effects. A total of 14 eyes of 14 patients were identified. The median age was 61 years (range: 9–83), and 43% of the patients were female. Most patients (64%) had a prior primary surgical failure. After one MTX series, 10 eyes (72%) were attached, and 8 (57%) were free of PVR at a median follow-up of 11 months (range: 2–14). All failures after a single MTX series were successfully treated with repeat surgery and a second (n = 4) or third (n = 1) MTX series, for the final reattachment and PVR-free rates of 100%. None of the patients experienced treatment-limiting side effects. Therefore, multiple series of MTX injections can be tolerated if indicated in cases of aggressive PVR threatening the retina." @default.
- W4367678369 created "2023-05-03" @default.
- W4367678369 creator A5055290552 @default.
- W4367678369 creator A5064464948 @default.
- W4367678369 date "2023-04-30" @default.
- W4367678369 modified "2023-10-18" @default.
- W4367678369 title "Tolerability and Efficacy of Multiple Series of Intravitreal Methotrexate Injections for Complex Retinal Detachment Associated with Proliferative Vitreoretinopathy" @default.
- W4367678369 cites W1535800817 @default.
- W4367678369 cites W1980404110 @default.
- W4367678369 cites W2004349871 @default.
- W4367678369 cites W2020492718 @default.
- W4367678369 cites W2046034087 @default.
- W4367678369 cites W2055164201 @default.
- W4367678369 cites W2092465351 @default.
- W4367678369 cites W2114232337 @default.
- W4367678369 cites W2129524501 @default.
- W4367678369 cites W2522030588 @default.
- W4367678369 cites W2737736503 @default.
- W4367678369 cites W2932913473 @default.
- W4367678369 cites W2946904091 @default.
- W4367678369 cites W2948685543 @default.
- W4367678369 cites W3009016248 @default.
- W4367678369 cites W3033914835 @default.
- W4367678369 cites W3073806372 @default.
- W4367678369 doi "https://doi.org/10.3390/futurepharmacol3020029" @default.
- W4367678369 hasPublicationYear "2023" @default.
- W4367678369 type Work @default.
- W4367678369 citedByCount "0" @default.
- W4367678369 crossrefType "journal-article" @default.
- W4367678369 hasAuthorship W4367678369A5055290552 @default.
- W4367678369 hasAuthorship W4367678369A5064464948 @default.
- W4367678369 hasBestOaLocation W43676783691 @default.
- W4367678369 hasConcept C118487528 @default.
- W4367678369 hasConcept C120665830 @default.
- W4367678369 hasConcept C121332964 @default.
- W4367678369 hasConcept C126322002 @default.
- W4367678369 hasConcept C141071460 @default.
- W4367678369 hasConcept C197934379 @default.
- W4367678369 hasConcept C2778375690 @default.
- W4367678369 hasConcept C2779059073 @default.
- W4367678369 hasConcept C2780428090 @default.
- W4367678369 hasConcept C2780827179 @default.
- W4367678369 hasConcept C2781059491 @default.
- W4367678369 hasConcept C61511704 @default.
- W4367678369 hasConcept C71924100 @default.
- W4367678369 hasConceptScore W4367678369C118487528 @default.
- W4367678369 hasConceptScore W4367678369C120665830 @default.
- W4367678369 hasConceptScore W4367678369C121332964 @default.
- W4367678369 hasConceptScore W4367678369C126322002 @default.
- W4367678369 hasConceptScore W4367678369C141071460 @default.
- W4367678369 hasConceptScore W4367678369C197934379 @default.
- W4367678369 hasConceptScore W4367678369C2778375690 @default.
- W4367678369 hasConceptScore W4367678369C2779059073 @default.
- W4367678369 hasConceptScore W4367678369C2780428090 @default.
- W4367678369 hasConceptScore W4367678369C2780827179 @default.
- W4367678369 hasConceptScore W4367678369C2781059491 @default.
- W4367678369 hasConceptScore W4367678369C61511704 @default.
- W4367678369 hasConceptScore W4367678369C71924100 @default.
- W4367678369 hasIssue "2" @default.
- W4367678369 hasLocation W43676783691 @default.
- W4367678369 hasOpenAccess W4367678369 @default.
- W4367678369 hasPrimaryLocation W43676783691 @default.
- W4367678369 hasRelatedWork W2005639104 @default.
- W4367678369 hasRelatedWork W2033111007 @default.
- W4367678369 hasRelatedWork W2055540927 @default.
- W4367678369 hasRelatedWork W2064353298 @default.
- W4367678369 hasRelatedWork W2416026931 @default.
- W4367678369 hasRelatedWork W2777639761 @default.
- W4367678369 hasRelatedWork W2794073754 @default.
- W4367678369 hasRelatedWork W2808128534 @default.
- W4367678369 hasRelatedWork W2900852205 @default.
- W4367678369 hasRelatedWork W3030525026 @default.
- W4367678369 hasVolume "3" @default.
- W4367678369 isParatext "false" @default.
- W4367678369 isRetracted "false" @default.
- W4367678369 workType "article" @default.